SCHEMBL117434

SCHEMBL117434

Cc1c(F)ccc2c(C(=O)O)cc(-c3ccc(Br)cc3)nc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
EPRS1 P07814 5/20 1.00
PPARA Q07869 1/20 0.57
AURKA O14965 1/20 0.55
DHODH Q02127 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL117482 0.87 EPRS1 (1.00) EPRS1PPARADHODH
SCHEMBL116047 0.78 EPRS1 (0.63) EPRS1DHODH
SCHEMBL117228 0.77 EPRS1 (0.65) EPRS1DHODH
SCHEMBL116062 0.76 EPRS1 (0.64) EPRS1PPARADHODH
SCHEMBL5792900 0.74 DHODH (0.78) EPRS1DHODH
SCHEMBL17211711 0.73 PPARA (1.00) EPRS1PPARADHODH
SCHEMBL31590457 0.73 PTGES (0.68) EPRS1DHODH
SCHEMBL117430 0.73 EPRS1 (0.79) EPRS1DHODH
SCHEMBL116080 0.72 EPRS1 (1.00) EPRS1AURKADHODH
SCHEMBL10915886 0.72 MCL1 (0.56) EPRS1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058133-A1 INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-03-08 US disclosed
US-20120058133-A1 INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058133-A1 INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF AARS1, GARS1, TRMT1 EPRS1 13/4885PPARA 1481/4885AURKA 3612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.